ArticleClinical pharmacology and therapeutics2021
Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19.
Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.Drug safety · 2026Article
- Letter to the Editor Regarding "Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy".Advances in therapy · 2026Article
- Prevalence of diagnosed idiopathic hypersomnia among adults in the United States 2019-2023: analysis of healthcare claims.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Emerging uncertainty on the anti-aging potential of metformin.Ageing research reviews · 2025Review
- Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private-Public Partnership: 10 Lessons Learned from a Principled Approach to Rapid Pandemic RWE Generation.Therapeutic innovation & regulatory science · 2025Article
- The role of Open Access Data in democratizing healthcare AI: A pathway to research enhancement, patient well-being and treatment equity in Andalusia, Spain.PLOS digital health · 2024Article
- Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.Frontiers in immunology · 2024Article
- Totality of evidence of the effectiveness of repurposed therapies for COVID-19: Can we use real-world studies alongside randomized controlled trials?Clinical and translational science · 2023Article
- Review
- Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies.JAMA network open · 2023Article
- Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C).BMC medical research methodology · 2023Article
- Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.Vaccine · 2023Article
- Using administrative healthcare data to evaluate drug repurposing opportunities for cancer: the possibility of using beta-blockers to treat breast cancer.Frontiers in pharmacology · 2023Article
- Noninterventional studies in the COVID-19 era: methodological considerations for study design and analysis.Journal of clinical epidemiology · 2023Article
- Use of Open Claims vs Closed Claims in Health Outcomes Research.Journal of health economics and outcomes research · 2023Article
- What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.JAMA network open · 2022Article
- Early Real-World Data to Assess Benefits and Risks of COVID-19 Vaccines: A Systematic Review of Methods.Vaccines · 2022Article
- Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies.Hospital pharmacy · 2022Article
- No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease.Research and practice in thrombosis and haemostasis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The emergence and global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an urgent need for evidence on medical interventions and outcomes of the resulting disease, coronavirus disease 2019 (COVID-19). Although many randomized controlled trials (RCTs) evaluating treatments and vaccines for COVID-19 are already in progress, the number of clinical questions of interest greatly outpaces the available resources to conduct RCTs. Therefore, there is growing interest in whether nonrandomized real-world evidence (RWE) can be used to supplement RCT evidence and aid in clinical decision making, but concerns about nonrandomized RWE have been highlighted by a proliferation of RWE studies on medications and COVID-19 outcomes with widely varying conclusions. The objective of this paper is to review some clinical questions of interest, potential data types, challenges, and merits of RWE in COVID-19, resulting in recommendations for nonrandomized RWE designs and analyses based on established RWE principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.